Quince Therapeutics, Inc. 8-K

What Happened
Quince Therapeutics, Inc. (QNCX) filed an 8-K reporting that its board approved a 1-for-20 reverse stock split. Stockholders previously authorized a reverse split in a range of 1-for-10 to 1-for-100 at the June 11, 2026 annual meeting. The company filed a Certificate of Amendment on June 26, 2026, which will become effective at 11:59 p.m. Eastern Time on June 29, 2026. Shares will begin trading on a split-adjusted basis on the Nasdaq Global Select Market at market open on June 30, 2026.

Key Details

• Reverse split ratio: 1-for-20 (every 20 shares combined into 1 share).
• Shares outstanding: 19,559,257 immediately before; approximately 977,963 immediately after effectiveness.
• Trading: New CUSIP 22053A305 effective June 30, 2026; ticker symbol remains "QNCX."
• Other effects: Outstanding stock options and warrants will be proportionally adjusted; fractional shares will be paid in cash; Equiniti Trust Company, LLC appointed as exchange/transfer agent.

Why It Matters
A reverse stock split reduces the number of shares outstanding and increases the per-share price proportionally but does not change each holder’s percentage ownership (except for cashing out fractional shares). The split does not change the rights or preferences of the common stock. Investors should see their broker accounts automatically adjusted (subject to broker processes) and expect option/warrant exercise prices and share counts to be adjusted proportionally. Review broker communications and the company’s Certificate of Amendment for full details.